Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
(NASDAQ: IMUX) Delayed: 10.83 +0.21 (1.98%)
Previous Close $10.62    52 Week High $ 
Open $10.86    52 Week Low $ 
Day High $11.07    P/E N/A 
Day Low $10.47    EPS $ 
Volume 468,662